Literature DB >> 21063925

Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Radojka M Savic1, France Mentré, Marc Lavielle.   

Abstract

Analysis of longitudinal ordered categorical efficacy or safety data in clinical trials using mixed models is increasingly performed. However, algorithms available for maximum likelihood estimation using an approximation of the likelihood integral, including LAPLACE approach, may give rise to biased parameter estimates. The SAEM algorithm is an efficient and powerful tool in the analysis of continuous/count mixed models. The aim of this study was to implement and investigate the performance of the SAEM algorithm for longitudinal categorical data. The SAEM algorithm is extended for parameter estimation in ordered categorical mixed models together with an estimation of the Fisher information matrix and the likelihood. We used Monte Carlo simulations using previously published scenarios evaluated with NONMEM. Accuracy and precision in parameter estimation and standard error estimates were assessed in terms of relative bias and root mean square error. This algorithm was illustrated on the simultaneous analysis of pharmacokinetic and discretized efficacy data obtained after a single dose of warfarin in healthy volunteers. The new SAEM algorithm is implemented in MONOLIX 3.1 for discrete mixed models. The analyses show that for parameter estimation, the relative bias is low for both fixed effects and variance components in all models studied. Estimated and empirical standard errors are similar. The warfarin example illustrates how simple and rapid it is to analyze simultaneously continuous and discrete data with MONOLIX 3.1. The SAEM algorithm is extended for analysis of longitudinal categorical data. It provides accurate estimates parameters and standard errors. The estimation is fast and stable.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063925      PMCID: PMC3032088          DOI: 10.1208/s12248-010-9238-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  19 in total

1.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.

Authors:  R A O'REILLY; P M AGGELER; L S LEONG
Journal:  J Clin Invest       Date:  1963-10       Impact factor: 14.808

2.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

3.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.

Authors:  Siv Jönsson; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

5.  A random effects model for ordinal responses from a crossover trial.

Authors:  F Ezzet; J Whitehead
Journal:  Stat Med       Date:  1991-06       Impact factor: 2.373

6.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

7.  Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.

Authors:  R A O'Reilly; P M Aggeler
Journal:  Circulation       Date:  1968-07       Impact factor: 29.690

8.  Population pharmacodynamic model for ketorolac analgesia.

Authors:  J W Mandema; D R Stanski
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

9.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

10.  Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Authors:  Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.410

View more
  6 in total

1.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

2.  A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.

Authors:  Andy R Eugene; Jolanta Masiak
Journal:  Nord J Psychiatry       Date:  2017-05-09       Impact factor: 2.202

3.  Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations.

Authors:  Andy R Eugene
Journal:  Int J Clin Pharmacol Toxicol       Date:  2016-05-19

4.  Evaluation of estimation methods and power of tests of discrete covariates in repeated time-to-event parametric models: application to Gaucher patients treated by imiglucerase.

Authors:  Marie Vigan; Jérôme Stirnemann; France Mentré
Journal:  AAPS J       Date:  2014-02-26       Impact factor: 4.009

5.  Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Authors:  Patumrat Sripan; Sophie Le Coeur; Billy Amzal; Lily Ingsrisawang; Patrinee Traisathit; Nicole Ngo-Giang-Huong; Kenneth McIntosh; Tim R Cressey; Suraphan Sangsawang; Boonsong Rawangban; Prateep Kanjanavikai; Jean-Marc Tréluyer; Gonzague Jourdain; Marc Lallemant; Saïk Urien
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

6.  Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data.

Authors:  Martín Umpiérrez; Natalia Guevara; Manuel Ibarra; Pietro Fagiolino; Marta Vázquez; Cecilia Maldonado
Journal:  Biomed Res Int       Date:  2021-04-08       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.